Advertising Survey

We would like your input on how advertising is currently used in the site.

Please take this short survey to help us out.

Hide this message

Calcium Channel Blockers

This PatientPlus article is written for healthcare professionals so the language may be more technical than the condition leaflets. You may find the abbreviations list helpful.

Introduction

Calcium channel blockers (CCBs) were developed in the 1970s and are now widely used.

Mode of action
CCBs all inhibit inward movement of calcium ions through the slow channels of active membranes especially in:

  • Cells of the myocardium (negative inotropic effect/myocardial depression)
  • Cells within the His-Purkinje system of the heart (impairment of atrioventricular conduction)
  • Cells of vascular smooth muscle (dilatation of coronary and peripheral arteries)

Because the various drugs differ in the relative affinity for these sites, a different balance of therapeutic effects is seen and hence differing indications, efficacy, contra-indications and side-effects. There are 3 subclasses of CCB:

Dihydropyridine calcium channel blockers (drugs ending in 'pine')

Reduce systemic vascular resistance and arterial pressure. Examples include:

  • Nifedipine - has more affinity for vascular smooth muscle and less for other sites. Hence it's value in Raynaud's disease. It rarely precipitates heart failure, as negative inotropic effects are offset by reduction in afterload. Longer-acting preparations should only be used for angina (rarely) and hypertension.
  • Nicardipine - is similarly effective on smooth muscle and used for angina prophylaxis and hypertension. It is not licensed for use in Raynaud's disease.
  • Amlodipine and felodipine - similarly, do not adversely affect myocardial contractility (with the risk of heart failure) and have a longer duration of action than nifedipine, making them useful in hypertension and angina. All are valuable in angina associated with coronary vasospasm. Side-effects relate to vasodilatation and may improve after a few days (headache, flushing).
  • Isradipine, lacidipine and lercanidipine - again, are similar in effect to nifedipine but are only indicated for hypertension.
  • Nimodipine - is similar to nifedipine but has an enhanced, selective effect on the cerebral arteries. This makes it useful for cerebral artery spasm and it is used solely for this purpose after subarachnoid haemorrhage (to prevent ischaemic deficit).

Phenylalkylamine calcium channel blockers

Used in angina and effects include reduced myocardial oxygen demand and reversal of coronary vasospasm with minimal peripheral vasodilation. Examples include:

  • Verapamil - is very negatively inotropic, impairs atrioventricular conduction, so slowing heart rate and lowering blood pressure. As a consequence it is used for angina, hypertension and supraventricular tachycardias (SVTs) but can also precipitate heart failure, cause hypotension, exacerbate conduction disorders and is contra-indicated with beta blockers.

Benzothiazepine calcium channel blockers

Intermediate between above 2 and has both cardio-depressant and vasodilatory effects. Examples include:

  • Diltiazem - is effective in angina and the longer-acting formulation in hypertension. It is less negatively inotropic than verapamil but should still be used cautiously with beta blockers.

Indications

  • Angina
  • Hypertension
  • Raynaud's Phenomenon (separate article)
  • Supraventricular arrhythmias
  • Ischaemic neurological deficit after subarachnoid haemorrhage
  • Prophylaxis for cluster headache

Evidence of efficacy

  • Angina:
    • Consensus that CCBs are effective in reducing symptoms in stable angina.
    • No significant differences compared with beta blockers in frequency of angina, exercise duration, mortality, quality of life.1,2,3
    • No significant difference compared with isosorbide mononitrate in frequency of attacks or quality of life, but peripheral oedema more of a problem.4
  • Hypertension:
    • Lowering blood pressure prevents strokes and ischaemic heart disease.5 CCBs are a key therapeutic choice in the major guidelines for the treatment of hypertension.
  • Raynaud's disease:
    • Nifedipine and diltiazem are the mainstay of medical treatment.
    • Nifedipine has been shown consistently to reduce frequency and severity of attacks in primary Raynaud's disease but is associated with expected adverse effects (see below).6,7,8 In one typical study 19 out of 21 sufferers preferred nifedipine to placebo but 30% reported side-effects.7
    • The evidence base for amlodipine and diltiazem is not strong.
  • Supraventricular arrhythmias:
    • Intravenous verapamil and diltiazem have been found equally effective at reducing heart rate at 10 or 30 minutes compared with placebo in atrial flutter and atrial fibrillation but use of verapamil could be limited by hypotension.9,10
  • Cluster headache:
    • Verapamil is used (unlicensed indication) to help reduce the severity of cluster attacks and there seems consensus from patient groups and clinicians that it is useful. It has been reported to cause bradycardia and atrioventricular block so further research is needed.11

Common adverse effects

These can be predicted from the type of CCB and mode of action, as already illustrated. Examples include:

  • Myocardial effects:
    • Hypotension
    • Heart failure
  • Conduction effects:
  • Vascular smooth muscle:
    • Flushing
    • Oedema
    • Headaches
    • Rashes
  • Other effects:

Cautions and contra-indications

Again, these can be predicted from the type of CCB and mode of action. Individual drug monographs need to be reviewed. Some examples include:

  • Cardiovascular: shock, unstable angina, significant aortic stenosis, bradycardia, heart failure, etc.
  • Avoidance of grapefruit juice with felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine and verapamil. This may affect metabolism.
  • Sudden withdrawal of CCBs may exacerbate angina - see separate article Angina Pectoris.

These are best considered under each individual drug.

Monitoring and follow-up

This will be determined largely by the condition being treated. Blood pressure and electrocardiography monitoring may be warranted but are best decided upon an individual basis.


Document references

  1. Destors JM, Boissel JP, Philippon AM, et al; Controlled clinical trial of bepridil, propranolol and placebo in the treatment of exercise induced angina pectoris. B.I.S. Research Group. Fundam Clin Pharmacol. 1989;3(6):597-611. [abstract]
  2. Singh S; Long-term double-blind evaluation of amlodipine and nadolol in patients with stable exertional angina pectoris. The Investigators of Study 152. Clin Cardiol. 1993 Jan;16(1):54-8. [abstract]
  3. Vliegen HW, van der Wall EE, Niemeyer MG, et al; Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris. J Cardiovasc Pharmacol. 1991;18 Suppl 9:S55-60. [abstract]
  4. Hall R, Chong C; A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina. Cardiology. 2001;96(2):72-7. [abstract]
  5. Lawes CM, Bennett DA, Feigin VL, et al; Blood pressure and stroke: an overview of published reviews. Stroke. 2004 Apr;35(4):1024. [abstract]
  6. Sarkozi J, Bookman AA, Mahon W, et al; Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol. 1986 Apr;13(2):331-6. [abstract]
  7. Gjorup T, Kelbaek H, Hartling OJ, et al; Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J. 1986 Apr;111(4):742-5. [abstract]
  8. Waller DG, Challenor VF, Francis DA, et al; Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol. 1986 Oct;22(4):449-54. [abstract]
  9. Phillips BG, Gandhi AJ, Sanoski CA, et al; Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997 Nov-Dec;17(6):1238-45. [abstract]
  10. Siu CW, Lau CP, Lee WL, et al; Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med. 2009 Jul;37(7):2174-9; quiz 2180. [abstract]
  11. Cohen AS, Matharu MS, Goadsby PJ; Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology. 2007 Aug 14;69(7):668-75. [abstract]

Internet and further reading

  • Angina-stable, Clinical Knowledge Summaries (September 2009)
  • Hypertension, Clinical Knowledge Summaries (July 2009)
  • Abrams J; Clinical practice. Chronic stable angina. N Engl J Med. 2005 Jun 16;352(24):2524-33.

Acknowledgements

EMIS is grateful to Dr Gurvinder Rull for writing this article and to Dr Richard Draper for earlier versions. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2009.
Document ID: 178
Document Version: 7
Document Reference: bgp24994
Last Updated: 20 Aug 2009
Provide feedback